• Caribou Biosciences launched a strategic review to maximize stockholder value, weighing options such as a merger or sale.
• Plans to halt development of vispa-cel for r/r B cell non-Hodgkin lymphoma, despite being positioned for a pivotal trial.
• Also discontinuing CB-011 for r/r multiple myeloma, citing a tougher financing market for allogeneic CAR-T therapies.
• Workforce and cost cuts set to follow, with most reductions expected to be completed in the fourth quarter of 2026.
• Cash, cash equivalents, and marketable securities totaled $113.8 million as of June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED9840754) on October 06, 2026, and is solely responsible for the information contained therein.